Allison Betof Warner
Overview
Explore the profile of Allison Betof Warner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smithy J, Schoenfeld A, Betof Warner A
Transplant Cell Ther
. 2025 Mar;
31(3S):S626-S634.
PMID: 40089331
The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating...
2.
Avutu V, Algazaq J, Seier K, Desir-Camille R, Qin L, Babatunde O, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39993596
Adoptive cellular therapy (ACT) is an increasingly widely used treatment approach for malignancy. While infectious complications of ACT have been well described in patients with hematologic malignancies, limited data are...
3.
Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno T, Carturan A, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39824527
Cancer immunotherapy-including immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT)-has become a standard, potentially curative treatment for a subset of advanced solid and liquid tumors. However, most patients with...
4.
Taparra K, Kekumano K, Benavente R, Roberto L, Gimmen M, Shontell R, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2430975.
PMID: 39212989
Importance: There are limited studies assessing stage at diagnosis and risk of death among all 5 federally defined races in the US among adolescent and young adult (AYA) patients with...
5.
Haanen J, Los C, Phan G, Betof Warner A
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e431608.
PMID: 38776509
Lifileucel or TIL has recently been FDA approved for metastatic melanoma patients as first cell therapy for a solid tumor. We discuss roll-out of TIL as new SOC and other...
6.
Smithy J, Kalvin H, Ehrich F, Shah R, Adamow M, Raber V, et al.
Clin Cancer Res
. 2024 May;
30(16):3407-3415.
PMID: 38767650
Purpose: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment. Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi). Exploratory biomarker...
7.
Chen S, Semenov Y, Alloo A, Bach D, Betof Warner A, Bougrine A, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38599660
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most...
8.
Betof Warner A, Hamid O, Komanduri K, Amaria R, Butler M, Haanen J, et al.
J Immunother Cancer
. 2024 Feb;
12(2).
PMID: 38423748
Adoptive cell therapy with autologous, ex vivo-expanded, tumor-infiltrating lymphocytes (TILs) is being investigated for treatment of solid tumors and has shown robust responses in clinical trials. Based on the encouraging...
9.
Malani R, Bhatia A, Betof Warner A, Yang J
Semin Neurol
. 2023 Nov;
43(6):859-866.
PMID: 37989214
Leptomeningeal metastases/diseases (LMDs) are a late-stage complication of solid tumor or hematologic malignancies. LMD is spread of cancer cells to the layers of the leptomeninges (pia and arachnoid maters) and...
10.
Hepner A, Versluis J, Wallace R, Allayous C, Brown L, Trojaniello C, et al.
Eur J Cancer
. 2023 Nov;
196:113441.
PMID: 37988842
Background: Anti-PD-1 therapy (PD1) either alone or with anti-CTLA-4 (CTLA4), has high initial response rates, however 20% of patients (pts) with complete response (CR) and 30% with partial response (PR)...